Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study

To compare ranibizumab with focal/grid laser or a combination of both in diabetic macular edema (DME). Prospective, randomized, interventional, multicenter clinical trial. A total of 126 patients with DME. Subjects were randomized 1:1:1 to receive 0.5 mg of ranibizumab at baseline and months 1, 3, a...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Ophthalmology (Rochester, Minn.) Ročník 116; číslo 11; s. 2175 - 81.e1
Hlavní autori:	Nguyen, Quan Dong, Shah, Syed Mahmood, Heier, Jeffery S, Do, Diana V, Lim, Jennifer, Boyer, David, Abraham, Prema, Campochiaro, Peter A
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.11.2009
Predmet:	Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized Combined Modality Therapy Diabetic Retinopathy - drug therapy Diabetic Retinopathy - physiopathology Diabetic Retinopathy - surgery Diabetic Retinopathy - therapy Endpoint Determination Female Humans Injections Laser Coagulation Macular Edema - drug therapy Macular Edema - physiopathology Macular Edema - surgery Macular Edema - therapy Male Middle Aged Prospective Studies Ranibizumab Tomography, Optical Coherence Treatment Outcome Visual Acuity - physiology Vitreous Body
ISSN:	1549-4713
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!